You searched for supply of essential oils | Page 2 of 45

BioBlast® w/e 09 Sep 22: Lupin & I’rom’s denosumab, Lupin & DKSH to supply Alvotech products, Cipla/Alvotech’s AU biosimilar adalimumab approved, Formycon half year results, Celltrion’s tocilizumab IPRs instituted, Regeneron aflibercept studies, Organon’s AU biosimilars roadmap

by Naomi Pearce | Sep 12, 2022 | BioBlast®, Blog

Significant biosimilar activities this week include: 25 Aug 22 | JP | Lupin and I’rom sign licence for denosumab in Japan Lupin announced that it has entered into an exclusive licensing agreement with I’rom Group for biosimilar denosumab in Japan. Under the...

Celltrion Confirms Largest Quarterly Supply Deal in its History (US$323.6M)

by Bioblast Editor | Sep 25, 2023 | Biosimilars updates

KED Global reported that Celltrion Inc. will provide biosimilars worth ₩423.6B (US$323M) to its global sales and marketing affiliate Celltrion Healthcare Co., Celltrion’s largest supply deal. The supplies include Yuflyma® (adalimumab, biosimilar to AbbVie’s Humira®),...

COVID-19 – Patent Rights in the Time of a Pandemic

by Pearce IP | Aug 27, 2020 | Blog

First published in Australian Intellectual Property Law update Vol. 33, No. 2, Jun 2020: 35-38 The COVID-19 pandemic and the urgent global need for effective treatments and/or a vaccine has implications for Australia’s new Crown use and compulsory licencing patent...

STADA and Xbrane announce NHS supply of Ximluci® (ranibizumab), a biosimilar to Roche/Genentech’s Lucentis®

by Bioblast Editor | Apr 25, 2023 | Biosimilars updates

STADA and Xbrane announced they are supplying Ximluci® (a biosimilar to Roche/Genentech’s Lucentis® (ranibizumab)) in England under a NHS England Framework Agreement. Ximluci® is indicated for the treatment of retinal vascular disorders, including wet age-related...

Samsung Bioepis to Cease Supplying Low Concentration Formulations of Adalloce® (adalimumab) in Korea

by Bioblast Editor | Jan 15, 2024 | Biosimilars updates

Korea Biomed has reported that Samsung Bioepis will stop supplying the low concentration formulations of Adalloce®, biosimilar to AbbVie’s Humira® (adalimumab), in Korea. Samsung Bioepis will continue to supply Adalloce® in two high-concentration formulations:...